Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs
DEC 15 (Reuters) – A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while taking the companies’ blockbuster weight loss drugs before a judge in Pennsylvania. The U.S. Judicial Panel on Multidistrict Litigation, which manages…